As businesses face increasing complexity across procurement and commerce systems, Vertex is enhancing its integration with core platforms to simplify global compliance and reduce operational friction.

Vertex Pharmaceuticals has received a “Moderate Buy” consensus from 29 brokerages, with most analysts either holding or ...

In an era of rising complexity, rapid technology shifts, budget pressures, and uninsurable risks, traditional security approaches no longer suffice. Businesses need to understand where they're ...

Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

This was the stock's second consecutive day of gains.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Web Services is working on revamping its artificial intelligence cloud service, Bedrock, in an effort to make it easier for customers to use and compete with rivals such as Google (NASDAQ:GOOG) ...

Vertex estimates a target market of 150,000 patients after the expected approval in 2028. By 2030, I project Povetacicept to capture 10% of this niche market, which is valued at around $2 billion.

If so, you might want to own Vertex Pharmaceuticals (VRTX-0.14%) if you believe corporate CFOs are right about a recession coming. Vertex's fortunes were built on the back of its CF franchise.

The FBI has awarded Vertex Aerospace a potential five-year, $100 million contract to provide maintenance support services for the bureau’s fixed- and rotary-wing aircraft.. According to an award ...